XIFAXAN: payments to doctors
Payments that named XIFAXAN as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $41.9M
- Providers
- 93,514
- Transactions
- 821,334
- Average per transaction
- $51
The per-transaction average — $51 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 93,514 providers the average total is $448, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | $41,868,887 | 100.0% |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | $4,310 | 0.0% |
| Bausch & Lomb Americas Inc. | $61 | 0.0% |